SLC5A1 Antibody

What is SLC5A1 and why is it a significant research target?

SLC5A1 (solute carrier family 5 member 1), also known as SGLT1, is a 664-amino acid membrane-associated protein belonging to the Sodium:solute symporter (SSF) family. This protein functions as an electrogenic Na+-coupled sugar symporter that actively transports D-glucose or D-galactose across the plasma membrane with a Na+:sugar coupling ratio of 2:1 . SLC5A1 has gained significant research interest due to:

• Its primary role in transporting dietary monosaccharides from enterocytes to blood

• Overexpression in various cancer types including pancreatic, colorectal, hepatocellular, prostate, cervical, and ovarian cancers

• Association with poor prognosis in pancreatic cancer patients

• Potential as a therapeutic target in cancer treatment, particularly through its interaction with EGFR

Understanding SLC5A1 function provides insights into both normal physiology and pathological conditions, making antibodies against this protein valuable research tools.

How do I select the appropriate SLC5A1 antibody for my experiments?

When selecting an SLC5A1/SGLT1 antibody, consider the following methodological approach:

• Define your application requirements: Different antibodies are optimized for specific applications. Based on the search results, SLC5A1 antibodies are available for:

  • Western Blot (WB): Most common application, with dilutions ranging from 1:500-1:3000

  • Immunohistochemistry (IHC-P/IHC-Fr): Typically used at 1:100-1:2500 dilutions

  • Immunocytochemistry/Immunofluorescence (ICC/IF): Used at 1:100-1:1000 dilutions

  • ELISA, IP and Dot Blot: Less common but available applications

• Consider species reactivity: Verify that the antibody reacts with your species of interest. Available reactivity includes:

  • Human (most common)

  • Mouse

  • Rat

  • Other species (rabbit, avian, canine, porcine depending on supplier)

• Evaluate validation evidence: Look for antibodies with multiple validation methods:

  • Orthogonal validation (correlation with RNA-seq data)

  • Validation using independent antibodies

  • Validation across multiple tissue types

• Select appropriate clonality:

  • Polyclonal antibodies: Provide broader epitope recognition but potentially more background

  • Monoclonal antibodies: Offer high specificity but may be more sensitive to epitope changes

• Check immunogen sequence: Ensure the immunogen sequence doesn't have homology with other proteins to avoid cross-reactivity .

What are the optimal conditions for using SLC5A1 antibodies in Western blotting?

For optimal Western blot results with SLC5A1 antibodies, follow this methodological approach:

• Sample preparation:

  • Use appropriate lysis buffers that preserve membrane proteins

  • Include protease inhibitors to prevent degradation

  • For tissue samples: Based on search result , successful detection was achieved with lysates from human HepG2, 293T, rat kidney, rat NRK, and mouse kidney tissues

• Gel electrophoresis conditions:

  • Use 5-20% SDS-PAGE gel

  • Run at 70V (stacking gel)/90V (resolving gel) for 2-3 hours

  • Load approximately 30 μg of protein per lane under reducing conditions

• Transfer and blocking:

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

  • Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Antibody incubation:

  • Primary antibody: Use at 0.5 μg/mL (or follow manufacturer's recommendation, typically 1:500-1:3000 dilution)

  • Incubate overnight at 4°C

  • Secondary antibody: Anti-rabbit IgG-HRP at 1:5000 dilution

  • Incubate for 1.5 hours at room temperature

• Detection and expected results:

  • Develop using ECL detection system

  • Expected band size: Approximately 73 kDa for SLC5A1/SGLT1

  • Note that glycosylation may affect migration pattern

This protocol was validated for SLC5A1 detection in the sources, showing specific bands at the expected molecular weight.

How should I optimize immunohistochemistry protocols for SLC5A1 detection in FFPE tissues?

For optimal immunohistochemical detection of SLC5A1 in formalin-fixed paraffin-embedded (FFPE) tissues:

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) using pH 6 citrate buffer is recommended

  • Alternative: 10mM Tris-EDTA buffer (pH 8.0)

• Antibody dilution and incubation:

  • Typical dilution range: 1:1000-1:2500 for most commercial antibodies

  • For some antibodies, a broader range of 1:100-1:1000 may be used

  • Incubate according to manufacturer's protocol (typically overnight at 4°C)

• Expected staining patterns:

  • Positive control: Human duodenum shows strong staining (correlates with high RNA-seq expression)

  • Negative controls: Human cerebral cortex and prostate show minimal or no staining

  • Membranous staining pattern expected based on SLC5A1's cellular localization

• Validation approach:

  • Use orthogonal validation by comparing antibody staining with RNA-seq data

  • Compare staining patterns with independent antibodies targeting different SLC5A1 epitopes

  • Include tissue panels with known differential expression of SLC5A1

Based on the search results, appropriate validation of SLC5A1 antibodies for IHC should include comparison between tissues with high expression (duodenum) and low expression (cerebral cortex), with staining patterns correlating with RNA-seq data .

How can SLC5A1 antibodies be used to investigate its role in pancreatic cancer progression?

SLC5A1 antibodies can be instrumental in exploring the role of this transporter in pancreatic cancer through multiple methodological approaches:

• Expression analysis in patient samples:

  • Use IHC to compare SLC5A1 expression between pancreatic tumor tissues and adjacent non-tumorous tissues

  • Correlate expression levels with clinical parameters (tumor stage, patient survival)

  • The search results indicate SLC5A1 is significantly upregulated in pancreatic cancerous tissues compared to adjacent non-cancerous fractions

• Functional studies in cell models:

  • Employ SLC5A1 antibodies for:

    • Western blotting to confirm knockdown efficiency in CRISPR or shRNA experiments

    • Immunofluorescence to visualize subcellular localization

    • Co-immunoprecipitation to detect protein-protein interactions (e.g., with EGFR)

• Mechanistic investigations:

  • Combine SLC5A1 antibody-based detection with functional assays:

    • Glucose uptake measurements (utilizing fluorescent glucose analogs like 2-NBDG)

    • Cell cycle analysis (important as SLC5A1 knockdown arrests pancreatic cancer cells in G0/G1 phase)

    • Signaling pathway analysis (particularly AMPK/mTOR pathway)

• Protein-protein interaction studies:

  • Use SLC5A1 antibodies for co-immunoprecipitation to validate interaction with EGFR

  • Search result demonstrates that EGFR can bind with SGLT1 protein in pancreatic cancer cells

  • This interaction affects glucose uptake and subsequent cancer cell survival

• In vivo tumor model analysis:

  • Use SLC5A1 antibodies to confirm knockdown in xenograft tumors

  • Correlate with tumor growth, glucose uptake, and pathway activation

The research findings indicate that SLC5A1 inhibition suppresses pancreatic cancer growth both in vitro and in vivo, primarily by reducing glucose uptake and inducing AMPK-dependent mTOR suppression .

What methodologies can be used to investigate the interaction between SLC5A1 and EGFR in cancer cells?

Based on the search results showing important SLC5A1-EGFR interactions in pancreatic cancer , researchers can employ the following methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Use anti-SLC5A1 antibody to pull down the protein complex

  • Probe with anti-EGFR antibody to detect interaction

  • Alternatively, perform reverse Co-IP using anti-EGFR antibody

  • Include appropriate controls (IgG, lysate input)

  • This approach successfully demonstrated SLC5A1-EGFR binding in pancreatic cancer cells

• Proximity ligation assay (PLA):

  • Utilize both SLC5A1 and EGFR antibodies from different species

  • This technique allows visualization of protein interactions within intact cells

  • Quantify interaction signals in different cellular compartments

• Immunofluorescence co-localization:

  • Use fluorescently labeled SLC5A1 and EGFR antibodies

  • Analyze co-localization using confocal microscopy

  • Quantify using Pearson's correlation coefficient or Manders' overlap coefficient

• Mass spectrometry-based approaches:

  • Immunoprecipitate SLC5A1 using validated antibodies

  • Identify interaction partners through mass spectrometry

  • Validate EGFR interaction through orthogonal methods

• Functional validation of interaction:

  • Use siRNA/shRNA targeting EGFR and analyze effects on:

    • SLC5A1 expression levels (Western blot)

    • Glucose uptake (2-NBDG assay)

    • Cell viability

  • Research data shows EGFR knockdown reduces SLC5A1 protein expression and glucose uptake

• Correlation analysis in patient samples:

  • Analyze mRNA expression correlation between SLC5A1 and EGFR

  • The search results showed a positive correlation (P=0.0035) between SLC5A1 and EGFR expression in 149 patient samples from TCGA database

This methodological framework provides a comprehensive approach to validating and characterizing the SLC5A1-EGFR interaction in cancer research contexts.

How can I validate the specificity of an SLC5A1 antibody for my experimental system?

A systematic approach to validating SLC5A1 antibody specificity includes:

• Positive and negative control tissues/cells:

  • Positive controls: Tissues with known high SLC5A1 expression (duodenum)

  • Negative controls: Tissues with minimal expression (cerebral cortex, prostate)

  • The search results demonstrate this approach for validating antibodies NBP2-38748 and NBP2-33629

• Orthogonal validation with RNA-seq data:

  • Compare antibody staining intensity with RNA-seq expression levels across tissues

  • Search result shows this validation method for SLC5A1 antibodies

  • This approach confirms that staining intensity correlates with transcript abundance

• Validation with independent antibodies:

  • Compare staining patterns using antibodies targeting different epitopes

  • Search results show similar tissue distribution patterns between antibodies NBP2-38748 and NBP2-33629

• Knockdown/knockout validation:

  • Use CRISPR, shRNA, or siRNA to reduce SLC5A1 expression

  • Confirm reduction in antibody signal by Western blot

  • Search result demonstrates this approach in pancreatic cancer cells

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide

  • Loss of signal confirms specificity to the target epitope

• Checking epitope conservation:

  • For cross-species applications, verify epitope conservation

  • BLAST analysis of the peptide immunogen should show no homology with other proteins

These validation approaches provide comprehensive evidence for antibody specificity and are critical for ensuring reliable experimental results.

What are common challenges when working with SLC5A1 antibodies, and how can they be addressed?

Based on general knowledge of membrane protein antibodies and information from the search results, researchers may encounter these challenges when working with SLC5A1 antibodies:

• Membrane protein extraction issues:

  • Challenge: Incomplete solubilization of membrane-associated SLC5A1

  • Solution: Use appropriate detergents (e.g., Triton X-100, NP-40, or specialized membrane protein extraction kits)

  • Evidence: The successful Western blot protocol in search result used whole cell lysates with appropriate buffers

• Post-translational modifications affecting recognition:

  • Challenge: Glycosylation sites on SLC5A1 may affect antibody binding

  • Solution: Consider enzymatic deglycosylation (PNGase F) before Western blotting

  • Evidence: Search result notes that glycosylation sites have been reported for SLC5A1

• Non-specific binding in Western blots:

  • Challenge: Multiple bands or high background

  • Solution:

    • Optimize blocking conditions (5% non-fat milk in TBS for 1.5 hours at room temperature)

    • Adjust antibody concentration (start with 0.5 μg/mL for Western blot)

    • Include appropriate controls

• Variable staining in IHC applications:

  • Challenge: Inconsistent or weak staining

  • Solution:

    • Optimize antigen retrieval (HIER pH 6 or pH 8 buffers)

    • Adjust antibody concentration (1:1000-1:2500 dilution range)

    • Extend primary antibody incubation time

• Cross-reactivity concerns:

  • Challenge: Potential binding to other SLC family members

  • Solution:

    • Select antibodies developed against unique regions of SLC5A1

    • Validate with positive and negative control tissues

    • Perform BLAST analysis of immunogen sequence

• Antibody performance variation between applications:

  • Challenge: An antibody working well in one application may not work in another

  • Solution:

    • Check application-specific validation data from suppliers

    • Consider application-specific antibodies (e.g., some antibodies are specifically validated for IHC-P but not WB)

By addressing these challenges with the suggested methodological solutions, researchers can achieve more reliable and reproducible results when working with SLC5A1 antibodies.

How can SLC5A1 antibodies be used to investigate glucose metabolism in cancer research?

SLC5A1 antibodies provide valuable tools for investigating altered glucose metabolism in cancer through several methodological approaches:

• Expression profiling across cancer types:

  • Use IHC with validated SLC5A1 antibodies to screen various cancer tissues

  • Compare with matched normal tissues

  • The search results indicate SLC5A1 overexpression in multiple cancer types including pancreatic, colorectal, hepatocellular, prostate, cervical, and ovarian cancers

• Correlation with glucose uptake:

  • Combine SLC5A1 immunostaining with fluorescent glucose analog (2-NBDG) uptake assays

  • Analyze correlation between SLC5A1 expression and glucose uptake capacity

  • Search result demonstrates that SLC5A1 knockdown reduces 2-NBDG uptake in pancreatic cancer cells

• Functional studies using genetic manipulation:

  • Use SLC5A1 antibodies to confirm knockdown/knockout efficiency

  • Measure effects on:

    • Glucose consumption rates

    • Lactate production

    • Cell proliferation and survival

    • Energy stress (AMPK activation)

  • Research shows SLC5A1 inhibition activates AMPK and suppresses mTOR signaling

• Metabolic pathway analysis:

  • Combine SLC5A1 antibody-based detection with metabolic pathway component analysis

  • Investigate the relationship between SLC5A1 expression and:

    • AMPK/mTOR signaling markers

    • Glycolytic enzyme expression

  • Search results show that SLC5A1 knockdown activates AMPK (increased p-AMPK) and suppresses mTOR (decreased p-mTOR)

• Response to glucose limitation:

  • Measure SLC5A1 expression changes under varying glucose concentrations

  • Research demonstrates that the effects of SLC5A1 inhibition can be rescued by high glucose (50 mM) and exacerbated by low glucose (0.5 mM)

• In vivo tumor metabolism studies:

  • Use SLC5A1 antibodies to correlate expression with FDG-PET imaging results

  • Analyze tumor sections for SLC5A1 expression and metabolic markers

  • Research shows SLC5A1 inhibition reduces pancreatic tumor growth in vivo

These methodological approaches using SLC5A1 antibodies can provide insights into the role of this transporter in cancer metabolism and potential therapeutic targeting.

What is the significance of SLC5A1-EGFR interaction in cancer research, and how can it be studied?

The SLC5A1-EGFR interaction represents an important connection between glucose metabolism and growth factor signaling in cancer. Based on search result , this interaction can be studied through:

This interaction has significant implications for understanding how cancer cells coordinate growth signaling with metabolic adaptation, and may provide novel therapeutic targeting strategies.

Table 1: Commercially Available SLC5A1 Antibody Applications and Specifications

Data compiled from search results